Vistagen Posts $13M Q1 FY2027 Loss, Cash Runway Into 2027, and Plans FDA Meeting on Fasedienol
VTGN sits 38% above its 52-week low of $0.198 on light trading volume (0.1× avg).
Summary
Vistagen reported a $13.0M quarterly net loss and $31.7M in cash, with runway into 2027 but not beyond a year. The company plans an FDA meeting this quarter to discuss fasedienol's path forward after PALISADE-4 failed its primary endpoint.
Key Events · Earnings and Guidance · VTGN
-
Q1 FY2027 Net Loss of $13.0M
Net loss was $13.0 million for the quarter ended June 30, 2026, compared with $15.1 million in the prior-year quarter. R&D expense was $10.9 million and G&A was $3.9 million.
-
Cash Runway Into 2027, Not Beyond a Year
Cash, cash equivalents, and marketable securities totaled $31.7 million as of June 30, 2026. Management believes this will fund operations into 2027 but not extend the runway more than a year from now.
-
FDA Meeting Planned This Quarter
The company plans to meet with the FDA during the current quarter to discuss a potential future Phase 3 registration-directed development pathway for fasedienol in social anxiety disorder.
-
Exploratory Efficacy Signal in Severe Patients
Post-hoc analyses of PALISADE-4 and a Phase 2 repeat dose study showed nominally statistically significant improvement in patients with very severe social anxiety disorder, though the primary endpoint was missed in the overall population.
Analysis · VTGN · Life Sciences
The first quarter of fiscal 2027 brought a net loss of $13.0 million, an improvement from $15.1 million a year earlier, with cash of $31.7 million as of June 30, 2026. Management now expects that cash to fund operations into 2027 but not beyond a year from now, a tighter runway than the previous 'into 2027' guidance. A meeting with the FDA is planned for this quarter to discuss a potential Phase 3 path for fasedienol after the PALISADE-4 failure, and exploratory analyses in very severe social anxiety patients showed nominally significant improvement. This update matters because it quantifies the company's financial position and sets a near-term regulatory catalyst that could determine whether the lead program has a future.
At the time of this filing, VTGN was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $0.20 to $5.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.